Search clinical trials for: Dapagliflozin 5mg

Total 13170 results

AstraZeneca
Bristol-Myers Squibb

Completed

Drug Interaction With Metformin

Healthy Male and Female Subjects

United States
International Bio service

Not yet recruiting

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Fayoum University
Cairo University

Not yet recruiting

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
University Medical Center Groningen
AstraZeneca

Enrolling by invitation

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria (ZODIAC)

Chronic Kidney Diseases

Netherlands, Canada, United States, Denmark, United Kingdom
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects (ULDS)

Type 2 Diabetes

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Amsterdam UMC, location VUmc

Completed

Renohemodynamic Effects of Combined empagliflOzin and LosARtan (RECOLAR)

Diabetes Mellitus, Type 2 | Diabetic Kidney Disease

Netherlands
Janssen Research & Development, LLC

Completed

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

Hepatitis C Virus

United States
Al-Balqa Applied University

Completed

Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers

Diabetes Mellitus

Jordan
Bayer

Recruiting

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Belgium, Spain, Taiwan, Korea, Republic of, Japan, Italy, Denmark, Israel, Canada, France, India, Netherlands, Germany
University of Sao Paulo General Hospital

Recruiting

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI) (SAFE-PCI)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury

Brazil
Janssen Research & Development, LLC

Completed

A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure (CHIEF-HF)

Heart Failure

United States
Sabyasachi Sen

Terminated

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Ottawa Heart Institute Research Corporation

Not yet recruiting

Dapagliflozin in STEMI Randomized Clinical Trial (DAPA STEMI)

Myocardial Infarction | ST Elevation Myocardial Infarction

Canada
Albina Nowak, MD

Not yet recruiting

Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

Fabry Disease
Mario Negri Institute for Pharmacological Research
AstraZeneca

Completed

Dapagliflozin in Non-diabetic Stage IV CKD (ADAPT)

Chronic Kidney Diseases

Italy
University Medical Center Groningen
AstraZeneca

Terminated

TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension (TIMOTHY)

Albuminuria

Netherlands
AstraZeneca

Completed

A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients (DAPACARD)

Diabetes Mellitus Type 2

Finland, Sweden
Kinderkrankenhaus auf der Bult

Completed

Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes (DAPA-IIT1)

Type 1 Diabetes

Germany
AstraZeneca
Bristol-Myers Squibb

Completed

Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers

Healthy

Sweden
The University of Texas Health Science Center at...

Completed

Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin (AZ11040)

Type II; Diabetes

United States
AstraZeneca
Bristol-Myers Squibb

Completed

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

Type 2 Diabetes

Mexico, Russian Federation, Spain, United States, Canada, Puerto Rico, Hungary, Peru, Romania, Poland, Germany, Czech Republic, India, Colombia, Denmark, Finland
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluation of Dapagliflozin Taken Twice-daily

Type 2 Diabetes

South Africa, Germany, Hungary, Romania, Slovakia, Switzerland, Ukraine
AstraZeneca
Bristol-Myers Squibb

Completed

A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

Healthy Volunteers

Germany
General and Teaching Hospital Celje

Completed

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients (ENDIS)

Diabetes Mellitus, Type 1 | Biomarkers | Endothelial Dysfunction | Arterial Stiffness | FMD | Incretins | Endothelial Progenitor Cells | SGLT 2 Inhibitors | Glucose Excursions | FPF

Slovenia
Chungbuk National University Hospital

Active, not recruiting

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy (LUCID)

Diabetes Mellitus, Type 2
Saint Luke's Health System

Completed

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure (EMBRACE-HF)

Heart Failure

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States
University Hospital Tuebingen

Terminated

Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment (DapaSaxaBBIT)

Type 2 Diabetes

Germany
Korea University Anam Hospital

Completed

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

Diabetes Mellitus

Korea, Republic of
McGill University Health Centre/Research Institute...

Recruiting

Empagliflozin in Acute Heart Failure (DRIP-AHF-1)

Chronic Kidney Diseases | Acute Heart Failure

Canada
Mount Sinai Hospital, Canada
Boehringer Ingelheim

Recruiting

Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes (EMPA post-GDM)

Gestational Diabetes

Canada
Peter Rossing

Completed

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes (DapKid)

Diabetic Nephropathy | Type 2 Diabetes

Denmark
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers

Healthy
Miulli General Hospital

Not yet recruiting

Empagliflozin and Atrial Fibrillation Treatment (EMPA-AF)

Heart Failure | Obesity | Diabetes Mellitus | Atrial Fibrillation

Italy
Bio-innova Co., Ltd

Not yet recruiting

Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

Healthy Subjects
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

Type 1 Diabetes

United States
Tanta University

Not yet recruiting

Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

Breast Cancer | Doxorubicin Induced Cardiomyopathy

Egypt
Mohammad Hussien Tantawy Soliman

Recruiting

Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI

Myocardial Infarction

Egypt
IRCCS Azienda Ospedaliera Universitaria San Martino...
AstraZeneca

Recruiting

GLUcose Transport and REnalPROtection in Chronic Kidney Disease (GLUTREPRO)

Hypertension | Diabetes Mellitus, Type 2 | Chronic Kidney Disease

Italy
Oslo University Hospital
University Hospital of North Norway; Haukeland University Hospital; St. Olavs...

Recruiting

Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?

Renal Failure | Kidney Transplant; Complications | Kidney Transplant Failure

Norway
National Taiwan University Hospital

Recruiting

A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease

Fatty Liver

Taiwan
Mansoura University

Active, not recruiting

Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

Chronic Kidney Diseases | Bone Diseases, Metabolic

Egypt
An-Najah National University

Completed

The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients

Peritoneal Dialysis Complication | Ultrafiltration Failure

Palestinian Territory, occupied
Saint Luke's Health System

Completed

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure (DEFINE-HF)

Chronic Heart Failure With Reduced Systolic Function

United States
AstraZeneca
Bristol-Myers Squibb

Completed

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Canada, Mexico, Puerto Rico
Instituto Mexicano del Seguro Social
Germán Ramón Bautista López; Luis Jonathan González; Rodolfo Guardado Mendoza; Gabriel...

Completed

Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI) (DAPA-AMI)

Heart Failure | Angina, Unstable | Acute Myocardial Infarction | Cardiovascular Morbidity

Mexico
Christopher Bell
AstraZeneca

Completed

Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?

Weight Loss

United States

3

Subscribe